Adagen Market Growth Prospects, Size, Regional Analysis and Forecast 2027
Market Overview: Introduced in 1990, Adagen serves as the pioneer alternative treatment for Severe Combined Immunodeficiency (SCID), offering a substitute to bone marrow transplants. SCID, an inherited primary immunodeficiency disease, manifests as an extreme immune deficiency, resulting in a weakened immune system incapable of combatting even mild infections. ADA-SCID, constituting 15-20% of...
0 Comments
0 Shares